37.114.204 REPORTS AND REPORT DEADLINES
(1) A local health officer must immediately report (within four hours) to the department by telephone the information cited in ARM 37.114.205(1) through (2) whenever a case of one of the following diseases is suspected or confirmed:
(d) Poliomyelitis, paralytic or nonparalytic;
(e) Severe Acute Respiratory Syndrome-associated Coronavirus (SARS-CoV) disease;
(g) Tularemia; or
(h) Viral hemorrhagic fevers.
(2) A local health officer must transmit by telephone or secure electronic means to the department the information required by ARM 37.114.205(1) and (2) for each suspected or confirmed case of one of the following diseases, within the time limit noted for each:
(a) Information about a case of one of the following diseases should be submitted within 24 hours by telephone by the local health officer:
(iii) Gastroenteritis outbreak;
(iv) Influenza-associated hospitalization and mortality;
(v) Novel influenza A virus infection;
(vii) Rabies in a human;
(viii) Rabies in an animal;
(x) Syphilis; and
(xi) Yellow fever.
(b) Information about a case of one of the following diseases should be submitted within seven calendar days after it is received by the local health officer:
(i) AIDS or HIV infection;
(iii) Arboviral Disease (neuroinvasive and non-neuroinvasive);
(v) Campylobacter enteritis;
(vii) Chlamydial trachomatis infection;
(ix) Colorado Tick Fever;
(xii) Dengue virus infections;
(xv) Haemophilus influenzae, invasive disease;
(xvi) Hansen's disease;
(xvii) Hantavirus pulmonary syndrome or infection;
(xviii) Hemolytic uremic syndrome, post diarrheal;
(xix) Hepatitis A, acute;
(xx) Hepatitis B, acute, chronic, perinatal;
(xxi) Hepatitis C, acute, infection past or present;
(xxii) Lead poisoning (blood levels ≥ 5 micrograms per deciliter for children 13 years of age or younger);
(xxv) Lyme disease;
(xxvii) Meningococcal disease (Neisseria meningitidis);
(xxxii) Rickettsiosis (Spotted Fever);
(xxxv) Streptococcus pneumoniae, invasive disease;
(xxxvi) Streptococcal toxic shock syndrome;
(xxxviii) Tickborne relapsing fever;
(xxxix) Toxic shock syndrome (non-streptococcal);
(xl) Transmissible spongiform encephalopathies;
(xli) Trichinellosis (Trichinosis);
(xliii) Typhoid Fever;
(xlv) Vibrio cholera infection (Cholera); and
(3) Each week during which a laboratory-confirmed case of influenza is reported to the local health officer, the officer must transmit by secure electronic means to the department on Friday of that week the total number of the cases of influenza reported.
(4) For any animal bite to a human by a species susceptible to rabies infection, the local health officer must report by secure electronic means to the department documentation of a rabies post-exposure prophylaxis recommendation and/or administration on a form provided by the department within seven calendar days of the recommendation or administration.
(5) A laboratory that performs a blood lead analysis must submit to the department, by the 15th day following the month in which the test was performed, a copy of all blood lead analyses performed that month, including analyses in which lead was undetectable.
(6) A laboratory that performs testing for respiratory syncytial virus (RSV) must submit to the department on a weekly basis, October 1 through June 1, a summary of the total number of RSV-specific antigen direct detection tests performed, the number of positive tests for each type, and the testing method (rapid or molecular testing) used for each specimen result on a form provided by the department.
(7) A laboratory that performs testing associated with HIV infection must report all test results that confirm HIV infection, all CD4 T-lymphocyte test results with or without confirmed HIV infection unless it is known that the test was performed in association with a disease other than HIV infection, positive p24 antigen assays, HIV nucleic acid viral load tests irrespective of results, positive results for qualitative nucleic acid tests for the detection of HIV infection and all test results for assays designed to assess HIV infection resistance to antiretroviral drugs.
History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13.